NDAORALTABLETPriority Review
Approved
Aug 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Protein Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Started Sep 2024
86 enrolled
Hairy Cell Leukemia
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Started Mar 2023
30 enrolled
Haematological MalignancyMelanomaThyroid Cancer, Papillary+9 more
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
Started Oct 2021
12 enrolled
Pancreas Cancer
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
Started Dec 2018
80 enrolled
Metastatic Melanoma
Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients
Started May 2018
9 enrolled
MelanomaMelanoma (Skin)Melanoma Stage
Loss of Exclusivity
LOE Date
Jun 6, 2032
76 months away
Patent Expiry
Jun 6, 2032